Lestaurtinib

Biological Activity for Lestaurtinib

Technical Data for Lestaurtinib

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility for Lestaurtinib

References for Lestaurtinib

References are publications that support the biological activity of the product.

• Daniel Beck Synthetic lethal screen demonstrates that a JAK2 inhibitor suppresses a BCL6 dependent IL10RA/JAK2/STAT3 pathway in high grade B-cell lymphoma J Biol Chem, 2016;0(0):. 2016 PMID: 27268052
• Deshpande A, Reddy MM, Schade GO Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia, 2012;26(4):708-15. 2012 PMID: 21926964
• Richards, Kathryn, Doble, Rosella, Wasson, Christop, Haider, Mohammed, Blair, G Eric, Wittmann, Miriam, Macdonald, Andrew Human papillomavirus E7 oncoprotein increases production of the anti-inflammatory interleukin-18 binding protein in keratinocytes. J Virol, 2014;88(8):4173-9. 2014 PMID: 24478434
• G?bler Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. J.Cell Mol.Med., ;17:265 PMID: 23301855
• Miknyoczki et al. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann.N.Y.Acad.Sci., 1999;880:252 PMID: 10415871
• Weisel et al. Effect of FLT3 inhibition on normal hematopoietic progenitor cells. Ann.N.Y.Acad.Sci., 2007;1106:190 PMID: 17442779
• Hexner et al. Lestaurinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood, 2008;111:5663 PMID: 17984313